Stereotaxis Q2 revenue $7.9M (+28% YoY), net loss $5.0M, cash $23.9M

Stereotaxis, Inc.

2023-Q2 EPS reported -$0.14 revenue$14,407,000

Revenue $7.9M, up 28% YoY; system revenue $3.3M (two Genesis systems), recurring revenue $4.6M.
Gross margin 53%; operating loss ($5.3M), net loss ($5.0M); adjusted net loss ($2.4M).
Cash $23.9M, no debt; expects year-end cash $22-24M; no additional financing needed.
Orders for two Genesis systems in Q2; system backlog $16M; guidance of double-digit revenue growth in 2023.
Announced strategic Abbott collaboration for EnSite X integration; MAGiC catheter study submitted.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Stereotaxis, Inc. reported second quarter ended June 30, 2023 results: revenue $7.9 million, net income ($5.0) million.

Period: second quarter ended June 30, 2023
Revenue: $7.9 million
Net income: ($5.0) million
Result: reported results

Exact text from the filing

its commercialization, and reach profitability without the need for additional financing.” 2023 Second Quarter Financial Results Revenue for the second quarter of 2023 totaled $7.9 million, a 28% year-over-year increase compared to $6.2 million in the prior year second quarter. System revenue for the quarter was $3.3 million and recurring revenue was $4.6 million,

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Stereotaxis, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-027465

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.